ID

46172

Descripción

Principal Investigator: Howard McLeod, Moffitt Cancer Center, Tampa, FL, USA MeSH: Prostatic Neoplasms,Neutropenia https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001002 The Cancer and Leukemia Group B (CALGB) 90401 trial compared docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer. A genome-wide association study using clinical outcomes and toxicities was conducted on the basis of data from CALGB patients who provided consent for pharmacogenomic studies and usable DNA

Link

dbGaP study=phs001002

Palabras clave

Versiones (2)
  1. 09.11.23 09.11.23 - Simon Heim
  2. 29.01.25 29.01.25 - Akane Nishihara
Titular de derechos de autor

Howard McLeod, Moffitt Cancer Center, Tampa, FL, USA

Subido en

29. Januar 2025

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

  • El más nuevo
  • Más antiguo
  • Popular
  • El más nuevo
    • El más nuevo
    • Más antiguo
    • Popular

Sin comentarios

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

dbGaP phs001002 Metastatic Castration-resistant Prostate Cancer GWAS

Inglés

Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type, and genotyping center of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.

5 formularios  
  1. StudyEvent: dbGaP phs001002 Metastatic Castration-resistant Prostate Cancer GWAS
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, source subject ID, and affection status of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
    3. Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
    4. Subject ID, neuropathy, neutropenia, genetic European status, age, sex, hemoglobin, palliative radiation, specimen(s) limitations, blood specimen, ethnicity, race, medical history of participant smoking and venous and arterial thromboembolism, arterial and or venous thromboembolism, BMI, diabetes, gastrointestinal tract, hemorrhage, Khorana risk status, anti-platelet or anti-coagulant use, and treatment arm assignment of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
    5. Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type, and genotyping center of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
pht005045
Descripción

pht005045

Alias
UMLS CUI [1,1]
C3846158
De-identified sample ID
Descripción

SAMPLE_ID

Tipo de datos

string

Alias
UMLS CUI [1,1]
C4684638
UMLS CUI [1,2]
C1299222
Body site where sample was collected
Descripción

BODY_SITE

Tipo de datos

string

Alias
UMLS CUI [1,1]
C0449705
Analyte type
Descripción

ANALYTE_TYPE

Tipo de datos

string

Alias
UMLS CUI [1,1]
C4744818
Tumor status
Descripción

IS_TUMOR

Tipo de datos

text

Alias
UMLS CUI [1,1]
C0475752
Cell or tissue type or subtype of sample
Descripción

HISTOLOGICAL_TYPE

Tipo de datos

string

Alias
UMLS CUI [1,1]
C2347026
UMLS CUI [1,2]
C0007634
UMLS CUI [1,3]
C0332307
UMLS CUI [2,1]
C2347026
UMLS CUI [2,2]
C0007634
UMLS CUI [2,3]
C0449560
UMLS CUI [3,1]
C1292533
UMLS CUI [3,2]
C0332307
UMLS CUI [4,1]
C1292533
UMLS CUI [4,2]
C0449560
Name of the center which conducted genotyping
Descripción

GENOTYPING_CENTER

Tipo de datos

string

Alias
UMLS CUI [1,1]
C1301943
UMLS CUI [1,2]
C5575037
UMLS CUI [1,3]
C1285573
Volver a la parte superior de la página

Similar models

Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type, and genotyping center of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.

5 formularios
  1. StudyEvent: dbGaP phs001002 Metastatic Castration-resistant Prostate Cancer GWAS
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, source subject ID, and affection status of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
    3. Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
    4. Subject ID, neuropathy, neutropenia, genetic European status, age, sex, hemoglobin, palliative radiation, specimen(s) limitations, blood specimen, ethnicity, race, medical history of participant smoking and venous and arterial thromboembolism, arterial and or venous thromboembolism, BMI, diabetes, gastrointestinal tract, hemorrhage, Khorana risk status, anti-platelet or anti-coagulant use, and treatment arm assignment of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
    5. Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type, and genotyping center of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
pht005045
C3846158 (UMLS CUI [1,1])
SAMPLE_ID
Item
De-identified sample ID
string
C4684638 (UMLS CUI [1,1])
C1299222 (UMLS CUI [1,2])
BODY_SITE
Item
Body site where sample was collected
string
C0449705 (UMLS CUI [1,1])
ANALYTE_TYPE
Item
Analyte type
string
C4744818 (UMLS CUI [1,1])
Item
Tumor status
text
C0475752 (UMLS CUI [1,1])
IS_TUMOR
Code List
Tumor status
CL Item
Is not a tumor (No)
C0027651 (UMLS CUI [1,1])
C1518422 (UMLS CUI [1,2])
HISTOLOGICAL_TYPE
Item
Cell or tissue type or subtype of sample
string
C2347026 (UMLS CUI [1,1])
C0007634 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C2347026 (UMLS CUI [2,1])
C0007634 (UMLS CUI [2,2])
C0449560 (UMLS CUI [2,3])
C1292533 (UMLS CUI [3,1])
C0332307 (UMLS CUI [3,2])
C1292533 (UMLS CUI [4,1])
C0449560 (UMLS CUI [4,2])
GENOTYPING_CENTER
Item
Name of the center which conducted genotyping
string
C1301943 (UMLS CUI [1,1])
C5575037 (UMLS CUI [1,2])
C1285573 (UMLS CUI [1,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial